摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-bromo-1-(quinolin-6-yl)aminoisoquinoline | 852570-81-1

中文名称
——
中文别名
——
英文名称
5-bromo-1-(quinolin-6-yl)aminoisoquinoline
英文别名
5-bromo-N-quinolin-6-ylisoquinolin-1-amine
5-bromo-1-(quinolin-6-yl)aminoisoquinoline化学式
CAS
852570-81-1
化学式
C18H12BrN3
mdl
——
分子量
350.217
InChiKey
GOKVKVYUZLHGRD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    515.8±45.0 °C(Predicted)
  • 密度:
    1.547±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.9
  • 重原子数:
    22
  • 可旋转键数:
    2
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    37.8
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    5-bromo-1-(quinolin-6-yl)aminoisoquinoline5-吲哚硼酸四(三苯基膦)钯 potassium carbonate 作用下, 以 1,4-二氧六环乙醇 为溶剂, 以52%的产率得到5-(indol-5-yl)-1-(quinolin-6-yl)aminoisoquinoline
    参考文献:
    名称:
    [EN] 1-AMINO-ISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH INAPPROPRIATE ALK5
    [FR] DERIVES DE 1-AMINO-ISOQUINOLINE POUR TRAITER DES MALADIES ASSOCIEES A UNE ALK5 INAPPROPRIEE
    摘要:
    公式(I)的化合物,其中R1代表一个苯基或萘基团(每个基团可任选地被一个或多个独立选自-OH,-C1-6烷基,C1-6卤代烷基,-OCH2OCH3,-C1-6烷氧基,-卤素的取代基取代),或者一个包含1、2或3个氮原子的单环或双环杂芳基团,可任选地被-C1-6烷氧基,-C1-6烷基,C1-6卤代烷基或=0取代;R2代表H,苯并咪唑基,苯并噻唑基,异喹啉基,喹啉基团或苯基(所说的苯基可任选地被-NR3R4,-C1-4烷氧基,-C1-6烷基,-CONR3R4,-SO2NR3R4,-NHCONR3R4,-NHCOC1-6烷基,-C1-6卤代烷基,-OCH2O-,-苯氧基(其中苯基部分可任选地被-NH2取代),-C1-3烷基,-C1-3烷氧基,-CF3,-含有一个或两个氮原子的五元杂芳基团取代)。R3和R4独立地选自H,-C1-6烷基,-C1-3烷基NR5R6;R5和R6独立地为H或C1-3烷基;或者其盐,溶剂化物,或生理功能衍生物。
    公开号:
    WO2005049577A1
  • 作为产物:
    描述:
    6-氨基喹啉5-溴-1-氯异喹啉盐酸碳酸氢钠 作用下, 以 1,4-二氧六环甲醇异丙醇乙酸乙酯 为溶剂, 反应 72.0h, 以78%的产率得到5-bromo-1-(quinolin-6-yl)aminoisoquinoline
    参考文献:
    名称:
    [EN] 1-AMINO-ISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH INAPPROPRIATE ALK5
    [FR] DERIVES DE 1-AMINO-ISOQUINOLINE POUR TRAITER DES MALADIES ASSOCIEES A UNE ALK5 INAPPROPRIEE
    摘要:
    公式(I)的化合物,其中R1代表一个苯基或萘基团(每个基团可任选地被一个或多个独立选自-OH,-C1-6烷基,C1-6卤代烷基,-OCH2OCH3,-C1-6烷氧基,-卤素的取代基取代),或者一个包含1、2或3个氮原子的单环或双环杂芳基团,可任选地被-C1-6烷氧基,-C1-6烷基,C1-6卤代烷基或=0取代;R2代表H,苯并咪唑基,苯并噻唑基,异喹啉基,喹啉基团或苯基(所说的苯基可任选地被-NR3R4,-C1-4烷氧基,-C1-6烷基,-CONR3R4,-SO2NR3R4,-NHCONR3R4,-NHCOC1-6烷基,-C1-6卤代烷基,-OCH2O-,-苯氧基(其中苯基部分可任选地被-NH2取代),-C1-3烷基,-C1-3烷氧基,-CF3,-含有一个或两个氮原子的五元杂芳基团取代)。R3和R4独立地选自H,-C1-6烷基,-C1-3烷基NR5R6;R5和R6独立地为H或C1-3烷基;或者其盐,溶剂化物,或生理功能衍生物。
    公开号:
    WO2005049577A1
点击查看最新优质反应信息

文献信息

  • [EN] SUBSTITUTE ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATHEROSCLEROSIS<br/>[FR] ISOQUINOLINES SUBSTITUEES UTILES POUR LE TRAITEMENT DE MALADIES DU TYPE CANCER ET ATHEROSCLEROSE
    申请人:GLAXO GROUP LTD
    公开号:WO2005049576A1
    公开(公告)日:2005-06-02
    A compound of Formula (I) wherein: One of R1 and R2 is H and the other represents - NHCONHR4 wherein R4 represents a phenyl or naphthyl group (which may be optionally substituted by one or more substituents independently selected from -C1-6 alkyl, -C1-6 haloalkyl, - CH2CH2CH2-, halogen, C1-6 alkoxy, C1-6 haloalkoxy, OH, NO2), C3-7 cycloalkyl or R4 together with the NH to which it is bonded forms a morpholino group and R3 is H or NHR5 wherein R5 is H, -quinolinyl or -isoquinolinyl, -(CONH)p phenyl (wherein p is 0 or 1 and the phenyl is optionally substituted by one or more substituents independently selected from halogen, -C1-6 alkyl, -C1-6 haloalkyl, -morpholino, -SO2NH2, benzothiazole (substituted by methyl)) or a salt, solvate, or physiologically functional derivative thereof.
    根据公式(I)的化合物,其中:R1和R2之一是H,另一个代表-NHCONHR4,其中R4代表一个苯基或基团(可以任选地被一个或多个独立选自-C1-6烷基,-C1-6卤代烷基,-CH2CH2CH2-,卤素,C1-6烷氧基,C1-6卤代烷氧基,OH,NO2的取代基所取代),C3-7环烷基或R4与它所连接的NH形成一个吗啉基团,并且R3是H或NHR5,其中R5是H,-喹啉基或-异喹啉基,-(CONH)p苯基(其中p是0或1,并且苯基可以任选地被一个或多个独立选自卤素,-C1-6烷基,-C1-6卤代烷基,-吗啉基,-SO2NH2,苯并噻唑(被甲基取代)的取代基所取代)或其盐,溶剂化物,或生理功能衍生物
  • 1-Amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5
    申请人:Washio Yoshiaki
    公开号:US20070072901A1
    公开(公告)日:2007-03-29
    A compound of Formula (I): or a salt or solvate thereof, wherein R 1 represents a phenyl or napthyl group, each of which is substituted by one or more substituents independently selected from —OH, —C 1-6 alkyl, C 1-6 haloalkyl, —OCH 2 OCH 3 , —C 1-6 alkoxy, and -halogen, or a mono or bicyclic heteroaryl group comprising 1, 2 or 3 nitrogen atoms, optionally substituted by —C 1-6 alkoxy, —C 1-6 alkyl, C 1-6 haloalkyl or ═O; R 2 represents H, benzimidazolyl, benzothiazolyl, piperonyl, isoquinolinyl, quinolinyl, or phenyl wherein said phenyl is optionally substituted by —NR 3 R 4 , —C 1-4 alkoxy, —C 1-6 alkyl, —CONR 3 R 4 , —SO 2 NR 3 R 4 , —NHCONR 3 R 4 , —NHCOC 1-6 alkyl, —C 1-6 haloalkyl, phenoxy, NH 2 substituted phenoxy, —C 1-3 alkyl, —C 1-3 alkoxy, —CF 3 , or -5 membered heteroaryl group comprising one or two nitrogen atoms; R 3 and R 4 are independently selected from H, —C 1-6 alkyl, —C 1-3 alkylNR 5 R 6 ; and R 5 and R 6 are independently H or C 1-3 alkyl.
    式(I)的化合物:或其盐或溶剂化物,其中R1代表苯基或基,每个基团都被一个或多个取代基独立地选择自—OH、—C1-6烷基、C1-6卤代烷基、—OCH2OCH3、—C1-6烷氧基和卤素,或者是一个含有1、2或3个氮原子的单环或双环杂芳基,可选地被—C1-6烷氧基、—C1-6烷基、C1-6卤代烷基或═O取代;R2代表H、苯并咪唑基、苯并噻唑基、哌啶基异喹啉基、喹啉基或苯基,其中所述苯基可选地被—NR3R4、—C1-4烷氧基、—C1-6烷基、—CONR3R4、—SO2NR3R4、—NHCONR3R4、—NHCOC1-6烷基、—C1-6卤代烷基、苯氧基、NH2取代的苯氧基、—C1-3烷基、—C1-3烷氧基、—CF3或一个含有一个或两个氮原子的5元杂芳基取代;R3和R4独立地选择自H、—C1-6烷基、—C1-3烷基NR5R6;R5和R6独立地选择自H或C1-3烷基。
  • SUBSTITUTE ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATHEROSCLEROSIS
    申请人:Washio Yoshiaki
    公开号:US20090291949A1
    公开(公告)日:2009-11-26
    A compound of Formula (I): or a salt or solvate thereof, wherein: One of R 1 and R 2 is H and the other represents —NHCONHR 4 , wherein R 4 represents a phenyl or naphthyl group which may be optionally substituted by one or more substituents independently selected from —C 1-6 alkyl, —C 1-6 haloalkyl, halogen, C 1-6 alkoxy, C 1-6 haloalkoxy, OH, NO 2 , C 3-7 cycloalkyl, indanyl, or R 4 together with the NH to which it is bonded forms a morpholino group; and R 3 is H or NHR 5 wherein R 5 is H, -quinolinyl or -isoquinolinyl, —(CONH) p phenyl wherein p is 0 or 1 and the phenyl is optionally substituted by one or more substituents independently selected from halogen, —C 1-6 alkyl, —C 1-6 haloalkyl, -morpholino, —SO 2 NH 2 , and methyl substituted benzothiazole.
    化合物的化学式为(I)或其盐或溶剂化合物,其中: R1和R2中的一个是H,另一个表示为—NHCONHR4,其中R4表示苯基或基,可以选择地由一个或多个取代基独立选择从—C1-6烷基,—C1-6卤代烷基,卤素,C1-6烷氧基,C1-6卤代烷氧基,OH,NO2,C3-7环烷基,吲哚基或R4与其连接的NH形成吗啡环基;而R3是H或NHR5,其中R5是H,-喹啉基或-异喹啉基,—(CONH)pphenyl,其中p为0或1,苯基可以选择地由一个或多个取代基独立选择从卤素,—C1-6烷基,—C1-6卤代烷基,-吗啡环基,—SO2NH2和甲基取代苯并噻唑基。
  • SUBSTITUTED ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATHEROSCLEROSIS
    申请人:GLAXO GROUP LIMITED
    公开号:EP1689717B1
    公开(公告)日:2007-12-26
  • 1-AMINO-ISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH INAPPROPRIATE ALK5 ACTIVITY
    申请人:GLAXO GROUP LIMITED
    公开号:EP1689718A1
    公开(公告)日:2006-08-16
查看更多